Table 2.
Concordance rate of biomarkers between primary and recurrent/metastatic breast cancer lesions.
| Primary lesion | N | Recurrent lesion | Concordance rate | Kappa | P value | |
|---|---|---|---|---|---|---|
| Positive* | Negative* | |||||
| ER status | 156 | 83.3% | 0.652 | <0.001 | ||
| Positive | 81 | 13 | ||||
| Negative | 13 | 49 | ||||
| PR status | 156 | 66.7% | 0.276 | 0.001 | ||
| Positive | 30 | 28 | ||||
| Negative | 24 | 74 | ||||
| HER2 status | 104** | 97.1% | 0.937 | <0.001 | ||
| Positive | 35 | 0 | ||||
| Negative | 3 | 66 | ||||
| Ki67 status | 145** | 68.3% | 0.152 | 0.169 | ||
| ≥14% | 87 | 14 | ||||
| <14% | 32 | 12 | ||||
*Positive group meant ≥14% in Ki67 status, and negative group meant <14% in Ki67 status.
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.
**HER2 and Ki67 discrepancy were unanalyzable in 52 and 11 patients due to “HER2 certain” or restricted quality of re-biopsy sample.
The bold values mean the difference is statistically significant.